Category: 53838-27-0

On April 11, 2002, Kaila, Neelu; Chen, Lihren; Thomas, Bert E. IV; Tsao, Desiree; Tam, Steve; Bedard, Patricia W.; Camphausen, Raymond T.; Alvarez, Juan C.; Ullas, Giliyar published an article.Safety of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate The title of the article was β-C-Mannosides as Selectin Inhibitors. And the article contained the following:

Potential E- and P-selectin inhibitors were synthesized to explore a hydrophobic area on the E-selectin surface and the PSGL-1 protein binding site on the P-selectin surface that was recently defined by crystallog. Three series of mannose-based compounds (libraries A, B, and C) were synthesized using solution phase parallel synthesis. Biol. evaluation of these compounds was done using two ELISA-based assays and transferred NOE (trNOE) experiments Some of the compounds showed better activity than sLex in the P-selectin assay. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Safety of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate

The Article related to combinatorial library mannoside preparation selectin inhibitor glycoprotein, structure activity mannoside preparation selectin inhibitor glycoprotein, aminodeoxy glycoside mannoside preparation selectin inhibitor glycoprotein psgl and other aspects.Safety of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On September 28, 2006, Koppel, Gary; Miller, Marvin published a patent.SDS of cas: 53838-27-0 The title of the patent was Preparation of oxoazetidineacetic acid derivatives as human vasopressin V1a receptor antagonists for the treatment of premenstrual disorders. And the patent contained the following:

Oxoazetidineacetic acid derivatives I [R1 = H, alkyl; R2 = H, alkyl, alkoxy, alkylthio, NC, OHC, alkylcarbonyl, (un)substituted aminocarbonyl; R3 = (un)substituted amino, amido, or ureido; R4 = (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, alkylcarbonyl, aralkyl, etc.; R5 = R7, R7CO; R6 = HO, HS, HO2C, (un)substituted ester, amide, alc., or thiol derivatives; R7 = HO2C, (un)substituted carboxylic acid ester or amide, carboxyalkyl, alkoxycarbonylalkyl, (un)substituted aminocarbonylalkyl], particularly (oxazolidinyl)(oxo)azetidineacetic acid derivatives such as II, are prepared as antagonists of human vasopressin V1a receptors for use in the treatment and prevention of premenstrual disorders. The preparation of I uses stereoselective [2+2] cycloadditions of ketenes generated from oxazolidinyl-substituted acid chlorides and amino acid-derived imines as the key steps. Data on the binding of the title compounds to human vasopressin V1a receptors is given; for example, II binds human vasopressin V1a receptors with an IC50 value of 1.84 nM. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).SDS of cas: 53838-27-0

The Article related to oxoazetidineacetic acid nonracemic preparation vasopressin v1a receptor antagonist, premenstrual disorder treatment vasopressin v1a receptor antagonist oxoazetidineacetic acid, beta lactamyl alkanoic acid preparation treatment premenstrual disorder and other aspects.SDS of cas: 53838-27-0

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On May 31, 2018, Zhang, Xuekai; Lu, Gang; Sun, Meng; Mahankali, Madhu; Ma, Yanfei; Zhang, Mingming; Hua, Wangde; Hu, Yuting; Wang, Qingbing; Chen, Jinghuo; He, Gang; Qi, Xiangbing; Shen, Weijun; Liu, Peng; Chen, Gong published an article.Reference of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate The title of the article was A general strategy for synthesis of cyclophane-braced peptide macrocycles via palladium-catalyzed intramolecular sp3 C-H arylation. And the article contained the following:

New methods capable of effecting cyclization, and forming novel three-dimensional structures while maintaining favorable physicochem. properties are needed to facilitate the development of cyclic peptide-based drugs that can engage challenging biol. targets, such as protein-protein interactions. Here, we report a highly efficient and generally applicable strategy for constructing new types of peptide macrocycles using palladium-catalyzed intramol. C(sp3)-H arylation reactions. Easily accessible linear peptide precursors of simple and versatile design can be selectively cyclized at the side chains of either aromatic or modified non-aromatic amino acid units to form various cyclophane-braced peptide cycles. This strategy provides a powerful tool to address the long-standing challenge of size- and composition-dependence in peptide macrocyclization, and generates novel peptide macrocycles with uniquely buttressed backbones and distinct loop-type three-dimensional structures. Preliminary cell proliferation screening of the pilot library revealed a potent lead compound with selective cytotoxicity toward proliferative Myc-dependent cancer cell lines. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Reference of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate

The Article related to cyclodepsipeptide cyclophane diastereoselective synthesis antitumor structure activity crystal structure, arylation palladium catalyst transition state ring strain energy dft, amino acid iodination esterification peptide coupling solid phase synthesis and other aspects.Reference of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On November 30, 2010, Baeza, Jose Luis; Bonache, M. Angeles; Garcia-Lopez, M. Teresa; Gonzalez-Muniz, Rosario; Martin-Martinez, Mercedes published an article.Related Products of 53838-27-0 The title of the article was 2-Alkyl-2-carboxyazetidines as γ-turn inducers: incorporation into neurotrophin fragments. And the article contained the following:

Conveniently substituted 2-alkyl-2-carboxyazetidine amino acids have been incorporated into NGF and NT3 tetrapeptide sequences to investigate their utility as reverse turn inducers (γ- vs. β-turns). Despite the presence of an Asp residue at i position, highly preferred in β-turns, mol. modeling and NMR studies indicated that the azetidine-containing peptides mainly stabilized γ-turn conformations. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Related Products of 53838-27-0

The Article related to alkyl carboxyazetidine amino acid turn gamma inducer neurotrophin peptide, solid phase peptide synthesis conformer turn conformation mol modeling, peptidomimetic hydrogen bond mol structure nmr md simulation, azetidine alkyl amino acid preparation gamma turn conformation and other aspects.Related Products of 53838-27-0

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On September 23, 1999, Buchanan, John; Bohacek, Regine; Vu, Chi B.; Luke, George P. published a patent.Name: (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate The title of the patent was Preparation of heterocyclyl phosphotyrosine derivatives as SH2-mediated signal transduction inhibitors. And the patent contained the following:

Heterocyclic phosphotyrosine derivatives were prepared for inhibiting intracellular signal transduction, especially intracellular signal transduction mediated by a PDGF receptor protein, EGF receptor protein, HER2/Neu receptor protein, fibroblast growth factor receptor protein, focal adhesion kinase protein, p130 protein, or p68 protein. For example, BOC-Tyr(PO3Bn2)-OH (BOC = tert-butoxycarbonyl; Bn = benzyl) and the thiazolylamine salt (I)·TFA (four step preparation given) were coupled, the phosphate deprotected, the amine acylated, and the carboxylic acid deprotected to form the title compound (II). In an assay for binding affinities to Src SH2, thirteen compounds of the invention were determined to have IC50 values of < 50μM. In an assay for binding affinities to Zap-70 SH2, fourteen compounds of the invention exhibited IC50 values of < 50μM. This invention also relates to pharmaceutical compositions containing the compounds and prophylactic and therapeutic methods involving pharmaceutical and veterinary administration of the compounds for proliferative disease, cancer, restenosis, osteoporosis, inflammation, allergies, cardiovascular disease, or immunosuppression. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Name: (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate

The Article related to peptide heterocyclyl phosphotyrosine preparation signal transduction inhibitor, antitumor heterocyclyl phosphotyrosine preparation antiosteoporotic antiinflammatory antiallergenic immunosuppressant, tyrosine phospho heterocyclyl preparation proliferative disease cardiovascular disease treatment and other aspects.Name: (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On March 24, 1993, Gilbert, Kevin; Williams, Peter D.; Hobbs, Doug W.; Evans, Ben E.; Veber, Daniel F. published a patent.Electric Literature of 53838-27-0 The title of the patent was Preparation of hydantoin and succinimide-substituted spiroindanylcamphorsulfonyl derivatives as oxytocin and vasopressin antagonists. And the patent contained the following:

Title compounds [I; R = substituted (unsaturated) 5- or 6-membered heterocyclyl containing 1-3 of N, O, or S], were prepared as oxytocin antagonists (no data). Thus, indene in THF was treated with LiN(SiMe3)2 and then with (ClCH2CH2)2NCO2CMe3 (preparation given) to give 1′-(tert-butoxycarbonyl)spiro(indene-1,4-piperidine), which was deprotected and acylated with (+)-10-comphorsulfonyl chloride followed by oximation and reduction with H2/Raney Ni to give endo-I (R = NH2). This was treated with 4-nitrophenyl chloroformate/Et3N, then with H-His-OMe.2HCl/Et3N, and finally with NaH in EtOH to give I (R = Q). The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Electric Literature of 53838-27-0

The Article related to bicycloheptylmethylsulfonylspiroindanepiperidine oxytocin antagonist, spiroindanepiperidine bicycloheptylmethylsulfonyl preparation, preterm labor prevention spiroindenepiperidine, dysmenorrhea treatment spiroindanepiperidine, vasopressin antagonist spiroindanepiperidine, hydantoin spiroindanylcamphorsulfonyl oxytocin antagonist and other aspects.Electric Literature of 53838-27-0

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On August 1, 2002, Arrhenius, Thomas; Chen, Mi; Cheng, Jie Fei; Huang, Yujin; Nadzan, Alex; Penuliar, Richard; Wallace, David; Zhang, Lin published a patent.HPLC of Formula: 53838-27-0 The title of the patent was Preparation of hydroxyhexafluoropropylazoles, -azines, and alkynes as malonyl-CoA decarboxylase inhibitors useful as metabolic modulators. And the patent contained the following:

Pharmaceutical compositions for inhibiting malonyl-CoA decarboxylase (MCD) comprising ZF2CCWX(AY) [W = (substituted) 5-membered nonaromatic heterocyclyl containing 1 double bond, 6-membered heterocyclyl containing 0-2 double bonds, alkynyl, 5-6 membered heteroaryl; A = O, S, NR3; X = H, CF2Z, CF3; XY = double bond; Z = F, Br, Cl, iodo, CF3], are claimed. Thus, 2-[2-(butylamino)thiazol-5-yl]-1,1,1,3,3,3-hexafluoropropan-2-ol (preparation given) was refluxed 4 h with EtNCO in benzene to give N-butyl-N’-ethyl-N-[5-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]thiazol-2-yl]urea. Tested title compounds inhibited MCD with IC50 = 0.024-3.71 μM. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).HPLC of Formula: 53838-27-0

The Article related to azole preparation malonyl coa decarboxylase inhibitor, thiazole hexafluorohydroxypropyl acylamino preparation malonyl coa decarboxylase inhibitor, fatty acid glucose metabolism disorder treatment azole, cardiovascular disease treatment azole preparation, angina pectoris treatment azine, obesity treatment alkyne, acidosis treatment azole, cancer treatment azole and other aspects.HPLC of Formula: 53838-27-0

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On April 22, 1999, Takahashi, Kanji; Sugiura, Tsuneyuki published a patent.Quality Control of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate The title of the patent was Preparation of aminobutanoic acid derivatives as inhibitors of matrix metalloproteinases. And the patent contained the following:

Aminobutanoic acid derivatives represented by general formula (I) and salts thereof [wherein R1 = CO2R10, CONHOR10, CONHNHR10, (CH2)nSR50, Y-P(:O)(OR51)2; R10 = H, C1-8 alkyl, Ph, phenyl- or C1-8 alkoxy-C1-8 alkyl, PhO2C, PhCH2O2C, C1-8 alkoxycarbonyl; wherein n = 0-3; R50 = H, C1-8 alkyl, C1-8-alkyl-carbonyl, PhCO, SH, C1-8 alkylthio, SPh; R51 = H, C1-8 alkyl, Ph; Y = single bond, CH2, O; R2-R7 = H, C2-8 alkenyl, (un)substituted SH, OH, or NH2, CO2H, C1-8 alkyl-carbonyl, C1-8 alkoxy-carbonyl, (un)substituted carbocyclyl or heterocyclyl, (un)substituted C1-8 alkyl or C2-8 alkenyl; or R3 and R4 or R5 and R6 together represents C1-8 alkylene; or R2 and R3, R4 and R5, or R6 and R7 together represent C2-8 alkylene; when R8 = H, (un)substituted C1-8 alkyl, or C1-8 alkoxy-carbonyl, R9 = (un)substituted carbocyclyl; or when R8 = (un)substituted carbocyclyl or heterocyclyl, R9 = (un)substituted C1-8 alkyl or C1-8 alkoxy, (un)substituted carbocyclyl; M = C1-8 alkylene; J = single bond, O, S, NH, C1-8 alkyl-N] are prepared and claimed. Also claimed are matrix metalloproteinases containing I as the active ingredients and drugs containing I as the active ingredients for the prevention and/or treatment of rheumatism, osteoarthritis, pathol. bone resorption, osteoporosis, periodontal diseases, interstitial nephritis, arteriosclerosis, pulmonary emphysema, hepatic cirrhosis, corneal injury, diseases due to metastasis and infiltration of cancer cells or proliferation thereof, autoimmune diseases (such as Crohn’s disease and Sjogren’s disease), diseases due to transmigration of white blood cells or infiltration thereof, neovascularization, multiple sclerosis, aortic aneurysm, or endometritis. For example, the title compound (II) showed IC50 of 26 nM against human stromelysin. A table and an ampule formulation containing II were described. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Quality Control of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate

The Article related to antiarteriosclerotics, antirheumatic agents, antitumor agents, aortic aneurysm, autoimmune disease, bone resorption, cirrhosis, corneal injury, crohn disease, endometritis, interstitial nephritis, leukocyte, metastasis inhibitors, multiple sclerosis, neovascularization, osteoarthritis, osteoporosis, periodontal disease and other aspects.Quality Control of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics